RESEARCH REPORT ON DR.REDDY’S LABORATORIES LIMITED

RESEARCH REPORT ON DR.REDDY’S LABORATORIES LIMITED

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

COMPANY PROFILE
Dr. Reddy’s Laboratories Ltd

Type Public
Traded as
NSE: DRREDDY
BSE: 500124
NYSE: RDY
NSE NIFTY 50 Constituent
ISIN
INE089A01023
Industry Pharmaceuticals
Founded 1984 (39 years ago)
Founders Anji Reddy
Headquarters Hyderabad; Telangana, India
Area served Worldwide
Key people G. V. Prasad
(Co-Chairman & MD)
Kallam Satish Reddy (Chairman)
Erez Israeli
(CEO)
Products Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, Biologics
Revenue ₹17,460 crore (US$2.2 billion) (2020)
Operating income
₹1,599 crore (US$200 million) (2020)
Net income
₹1,950 crore (US$240 million) (2020)
Total assets
₹23,156 crore (US$2.9 billion) (2020)
Total equity
₹15,499 crore (US$1.9 billion) (2020)
Number of employees 21,650 (March 2020)
Website www.drreddys.com

 FUNDAMENTALS

 SHAREHOLDING

FINANCIALS

 REVENUE

 NET PROFIT

 EPS

 BVPS

 

 

 ROE

 DEBT TO EQUITY

TECHNICAL ANALYSIS

BUY DRREDDY AT 4800 TARGET 5310, 5700 STOPLOSS 4295
(1-4 MONTHS)

RATIO ANALYSIS

Disclaimer: This research report is prepared by Shyam Advisory Limited, while making this report we have taken data from available sources and there may be errors in the data shown. We do not guarantee the accuracy of data and recommendation given in this report. Recommendation is for information purpose only.

“Investment in Securities market are subject to market risks. Read all the related documents carefully before investing.”